SCHEMBL10274436

SCHEMBL10274436

CCCc1cccc(C(=O)N2CCc3ccccc3C2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
ALDH1A1 P00352 3/20 0.63
PARP1 P09874 1/20 0.57
CYP3A4 P08684 2/20 0.54
CYP2C19 P33261 2/20 0.54
CYP2D6 P10635 1/20 0.54
HSP90AA1 P07900 2/20 0.54
HSP90AB1 P08238 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
HTT P42858 2/20 0.53
NPC1 O15118 2/20 0.53
TP53 P04637 1/20 0.53
LOX P28300 1/20 0.51
LOXL2 Q9Y4K0 1/20 0.51
ACACB O00763 1/20 0.51
NOTUM Q6P988 1/20 0.50
CYP2C9 P11712 1/20 0.50
GRM5 P41594 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1695970 0.91 HSP90AA1 (0.52) HPGDSMN1; SMN2ALDH1A1HSP90AA1HSP90AB1
SCHEMBL7899569 0.90 HPGD (0.66) HPGDSMN1; SMN2ALDH1A1PARP1CYP3A4
SCHEMBL1690513 0.86 HPGD (0.62) HPGDSMN1; SMN2ALDH1A1PARP1CYP3A4
SCHEMBL14393561 0.86 HPGD (0.68) HPGDSMN1; SMN2ALDH1A1CYP3A4CYP2C19
SCHEMBL12736229 0.82 TP53 (0.58) HPGDSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL13657383 0.80 SMN1; SMN2 (0.56) HPGDSMN1; SMN2ALDH1A1PARP1MEN1
SCHEMBL12846718 0.80 HPGD (0.71) HPGDSMN1; SMN2ALDH1A1CYP3A4CYP2C19
SCHEMBL1696130 0.80 AVPR2 (0.65) HPGDSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL7904938 0.80 HSP90AA1 (0.53) HPGDSMN1; SMN2ALDH1A1HSP90AA1HSP90AB1
SCHEMBL1696388 0.79 NPC1 (0.63) HPGDSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 HPGD 1339/4885SMN1; SMN2 4322/4885ALDH1A1 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.